Mr. Blake Salisbury is Senior Vice President, Business Development at Innovent Biologics. With nearly 35 years of experience in the pharmaceutical and biotechnology industry, he has played a central role in shaping Innovent’s evolution into a globally integrated biopharmaceutical partner.

Over the past decade, Mr. Salisbury has led or played a key role in more than 40 strategic collaborations with multinational pharmaceutical companies and leading China and regional biotech innovators, helping position Innovent at the forefront of cross-border drug development and commercialization. His work has focused on building long-term partnerships that leverage China’s development speed and scale to accelerate global innovation.

​

He led Innovent’s landmark partnership with Takeda Pharmaceuticals — one of the largest cross-border transactions between a China-based biopharmaceutical company and a global innovator — establishing a new model for shared development, profit participation, and co-commercialization. He also played a key role in advancing Innovent’s recent multi-product collaboration with Eli Lilly spanning discovery through proof-of-concept development in China. Earlier, he led the in-licensing of Mazdutide from Eli Lilly for China development, a therapy with the potential to become the leading obesity product in one of the world’s largest pharmaceutical markets.

Prior to joining Innovent, Mr. Salisbury spent nearly 24 years at Eli Lilly and Company, where he completed more than 50 transactions across research, development, and commercial-stage assets. He received his MBA from the Thunderbird Graduate School of Global Management.